Gathering health information for younger cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to create a comprehensive Childhood Cancer Registry for infants, children, adolescents, and young adults diagnosed with cancer. It involves collecting clinical and biological data to determine eligibility for future therapeutic clinical trials and developing a biorepository for ongoing research. Patients will undergo medical data reviews and biospecimen collection, including various biological samples, to support better treatment methods and care strategies. The registry will also facilitate future contact for non-therapeutic and prevention research studies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Enrollment must occur within 6 months of initial disease presentation OR within 6 months of refractory disease, disease progression, disease recurrence, second or secondary malignancy, or post-mortem
* Patients previously enrolled on ACCRN07 are eligible to enroll on Tracking Outcome, Registry and Future Contact components of APEC14B1 any time after they reach age of majority
* Patients with a known or suspected neoplasm that occurs in the pediatric, adolescent or young adult populations are eligible for enrollment as follows:

  * All cancer cases with an International Classification of Diseases for Oncology (ICD-O) histologic behavior code of one "1" (borderline), two "2" (carcinoma in situ) or three "3" (malignant)
  * All neoplastic lesions of the central nervous system regardless of behavior, i.e., benign, borderline or malignant
  * All neoplastic lesions of the kidney regardless of behavior, i.e., benign, borderline or malignant
  * The following other benign/borderline conditions:

    * Mesoblastic nephroma
    * Teratomas (mature and immature types)
    * Myeloproliferative diseases including transient myeloproliferative disease
    * Langerhans cell histiocytosis
    * Lymphoproliferative diseases
    * Desmoid tumors
    * Gonadal stromal cell tumors
    * Neuroendocrine tumors including pheochromocytoma
    * Melanocytic tumors, except clearly benign nevi
    * Ganglioneuromas
* Subjects must be =\< 25 years of age at time of original diagnosis, except for patients who are being screened specifically for eligibility onto a COG (or COG participating National Clinical Trials Network \[NCTN\]) therapeutic study, for which there is a higher upper age limit
* All patients or their parents or legally authorized representatives must sign a written informed consent and agree to participate in at least one component of the study; parents will be asked to sign a separate consent for their own biospecimen submission

  * If patients or their parents or legally authorized representatives have not signed the Part A subject consent form at the time of a diagnostic bone marrow procedure, it is recommended that they initially provide consent for drawing extra bone marrow using the Consent for Collection of Additional Bone Marrow; consent using the Part A subject consent form must be provided prior to any other procedures for eligibility screening or banking under APEC14B1

Where it's running

• Children's Hospital of Alabama
  Birmingham, Alabama, United States Recruiting
• USA Health Strada Patient Care Center
  Mobile, Alabama, United States Recruiting
• Providence Alaska Medical Center
  Anchorage, Alaska, United States Recruiting
• Kingman Regional Medical Center
  Kingman, Arizona, United States Recruiting
• Banner Children's at Desert
  Mesa, Arizona, United States Recruiting
• Phoenix Childrens Hospital
  Phoenix, Arizona, United States Recruiting

+229 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Principal investigator: Douglas S Hawkins — Children's Oncology Group

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Somatostatin analogues after PRRT for nonfunctional neuroendocrine tumors

  This study tests whether continuing somatostatin analogues after PRRT helps patients with nonfunctional neuroendocrine tumors compared with just observation.

  Recruiting Phase 3 Washington University School of Medicine · San Francisco, California and 1 other locations · NCT07842172

• See if virtual informed consent methods help people decide to join cancer research

  This trial tests whether virtual human communicators and different consent messages can influence cancer patients’ understanding and willingness to participate in research.

  Recruiting Mayo Clinic · Jacksonville, Florida · NCT07805083

• MK-2010 with Sac-TMT in advanced solid tumors

  This study tests MK-2010 combined with sacituzumab tirumotecan (sac-TMT) to see if it can help people with advanced solid tumors.

  Recruiting at 4 sites Phase 2 Merck Sharp & Dohme LLC · San Antonio, Texas and 3 other locations · NCT07785609

• AI-powered supportive care chatbot for young adult cancer survivors

  A chatbot driven by artificial intelligence is tested to help young adult cancer survivors manage symptoms and care needs after treatment.

  Recruiting University of Michigan Rogel Cancer Center · Ann Arbor, Michigan · NCT07772596

• Telehealth pharmacist-led opioid education for cancer patients

  This pilot tests a telehealth group education session led by a palliative care pharmacist to help adults with cancer use opioids more safely and effectively.

  Recruiting Fred Hutchinson Cancer Center · Seattle, Washington · NCT07737314

• Mindfulness program to help with symptoms in chronic graft-versus-host disease

  A mindfulness-based program is being tested to see if it can reduce patient-reported symptoms for adults with chronic graft-versus-host disease after a stem cell transplant.

  Recruiting City of Hope Medical Center · Duarte, California · NCT07733141

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.